AMGEN presents ‘encouraging’ AMG 133 weight loss results
Amgen revealed new Phase 1 data from AMG 133, a novel bispecific glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist...
top of page
Browse by category
Search
Browse by tag
bottom of page